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ABSTRACT
Background: Not only is depression associated with increased inflammation but inflammation is a risk
factor for the genesis of depression. Many of the environmental risk factors for depression are transduced
through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression
in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-
inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for
depression prevention.
Method: ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which
explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With
a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest
randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to
prevent depression.
Results: This paper presents the rationale for the study and presents a summary of the study design.
Conclusions: ASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of
the role of inflammation in depression.
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Introduction
The 2013 Global Burden of Disease study ranks
major depression as a principal contributor to
disease burden. In almost every other area of
health, preventative strategies have made a major
difference to disease incidence, whether it be
vaccination for infectious disease, smoking control
and lung cancer, clean water and diarrheal diseases,
or risk factor modification and cardiovascular
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disease. In stark contrast to the somatic medical
field, psychiatry is almost entirely lacking in
evidence-based prevention strategies. Preventive
interventions in psychiatry mainly consist of
adapted cognitive behavior type therapy given
to individuals with early or emerging symptoms
(Cuijpers et al., 2008). Notably, there are no
evidence-based preventative pharmacotherapies for
psychiatric disorders.
Current evidence suggests a possible etiological
role for inflammation in the genesis and patho-
physiology of depression. Increased mean plasma
levels of the inflammatory blood biomarkers, tumor
necrosis factor alpha (TNF-α), interleukin-6 (IL-
6), and C reactive protein (CRP) are found in
patients with clinical depression including the
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elderly (Pasco et al., 2010b). The possible link
between inflammation and depression raises the
question of whether the association is causal,
and if so, whether pharmacological suppression of
inflammation is effective in preventing depression.
ASPREE (ASPirin in Reducing Events in the
Elderly) is a National Institute on Aging (NIA) and
NHMRC supported 5 year randomized controlled
trial (RCT) of aspirin (100 mg daily) or placebo
in 19,000 healthy, older adults. Depression is a
secondary endpoint of the ASPREE principal trial
and this sub-study focuses further on depression,
aiming to study the impact of low-dose aspirin on
the incidence of this condition and to determine
whether the relationship between inflammation and
depression is likely to be causal (2013). ASPREE-D
is both one of the first trials to explore preventative
pharmacotherapy for psychiatric disorders, and will
be one of the largest RCTs ever in psychiatry, with
a sample size amply powered to detect the predicted
incidence. In addition to examining the efficacy
of aspirin in reducing depression in the elderly,
ASPREE-D will measure biomarkers from blood
samples collected from ASPREE participants to
confirm or refute whether inflammatory biomarkers
are risk biomarkers for depression genesis.
Aim
The primary aim of this sub-study (ASPREE-D)
is to determine if use of low-dose aspirin reduces
the risk of depression in healthy individuals aged
65 years or older.
Primary hypothesis
Low dose aspirin will reduce the risk of depression,
defined as a Centre for Epidemiologic Studies
Depression Scale (CES-D)-10 item scale score of
8 or above, at any post randomization time-point.
Secondary hypotheses
1. Higher levels of inflammatory biomarkers [TNF-
α, IL-6, or CRP] in plasma are associated with the
risk of depression.
2. 100 mg aspirin suppresses inflammation as
measured through the above plasma biomarkers.
3. The degree of suppression of inflammatory
markers is predictive of the effect of aspirin on risk
of depression.
4. Low-dose aspirin improves quality of life, assessed
using the Quality of life Short Form–12 (SF-12),
in healthy individuals over 65 years of age at least
in part by reducing depression.
5. Treatment with low-dose aspirin compared with
placebo-treatment in those with pre-existing
depression (high CES-D at baseline) will reduce
the severity of depression.
Background
Major depressive disorder and the elderly
Major Depressive Disorder (MDD) is common
across the lifespan. Prevalence estimates of de-
pression (MDD, minor depression, and dysthymic
disorder) in the elderly range from 10–15%
(Alexopoulos, 2005). Where individuals were
examined for a depressive episode at ages 70,
75, 79, 81, 83, and 85 years, the prevalence of
depression increased from 5.6% at age 70 to 13.0%
at age 85, indicating a significant burden of incident
episodes across this age span (Palsson et al., 2001).
Depression in the elderly is associated with a wide
range of adverse outcomes, including increased
mortality, increased dementia, and substantial
psychosocial disability (Ancill and Holliday, 1990).
With the rapid increase in the aged population
in developed countries, the societal impact of
depression will increase, hence the importance of
identifying approaches to reduce its impact.
Major depressive disorder and inflammation
While inflammation is a common accompaniment
of depression, a fundamental question is whether
inflammation contributes to the severity or genesis
of depressive symptoms or is a by-product of
depression. The most consistently elevated inflam-
matory markers in patients with MDD confirmed
by meta-analysis (Liu et al., 2012) are CRP, IL-6,
and TNFα. In addition, elevation of markers of cell
mediated immune activation such as IL-1-beta (IL-
1β), serum soluble IL-2 receptor and interferon-
γ have been identified in several studies (Maes
et al., 2012b). Exogenous cytokine administration
induces depression in volunteers and is arguably
the best human model of depression (Maes et al.,
2012a). Depression occurs at a substantially higher
rate in patients with inflammatory disorders such as
multiple sclerosis, psoriasis, rheumatoid arthritis,
and inflammatory bowel disease (Krishnadas and
Cavanagh, 2012).
Elevated cytokines such as TNFα are found in
both blood and brains of people with depression
who commit suicide (Dean et al., 2010). Pro-
inflammatory cytokines such as CRP, IL-6, TNFα,
and IL-10 affect serotonergic and other MDD-
related transmitter systems, and modulate synaptic
plasticity, which is similarly disrupted in MDD
(Krishnadas and Cavanagh, 2012). Inflammatory
cytokines can potentiate excitotoxic damage pro-
duced through NMDA receptor activation and
reduce neurogenesis (Moylan et al., 2013).
Levels of inflammatory biomarkers in plasma
increase with age (Jenny et al., 2012). Elevated
levels of inflammatory biomarkers including CRP,
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IL-6, and TNF-α may ante-date the onset of
depression in the elderly. Inflammatory markers,
especially IL-1β and IL-6, are reduced with
antidepressant treatment (Hiles et al., 2012). These
findings provide support for the use of immune
interventions that directly address this aspect of




Aspirin is a non-steroidal anti-inflammatory drug
that is an irreversible inhibitor of cyclooxygenase-
1 (COX-1) and COX-2. It stimulates endogenous
production of anti-inflammatory regulatory “brak-
ing signals”, including lipoxins, which dampen
the inflammatory response and reduce levels of
inflammatory biomarkers, including CRP, TNFα,
and IL–6, but not negative immunoregulatory
cytokines, such as IL-4 and IL-10.
Aspirin may reduce inflammatory changes in
the brain given that COX-1 is found in microglia
where it presumably has a role in modulating
neuro-inflammation (Berk et al., 2013). Aspirin has
a specific antithrombotic and thrombolytic action
through inhibition of COX-1 in platelets, which
may reduce the incidence of micro-vessel changes
and ischemic stroke (Berk et al., 2013). Since
aspirin reduces the incidence of vascular events,
including stroke, this decrease in cerebrovascular
burden could potentially contribute to reduce
the risk of depression. An exploratory hypothesis
that will be tested in ASPREE-D is whether
aspirin use reduces depressive episodes associated
with cerebrovascular and cardiovascular events.
Because of the particular contribution of vascular
disease to depression in the elderly, it seems
reasonable to assume that aspirin may also
play a therapeutic role through anti-thrombotic
pathways.
Aspirin and the suppression of
inflammation
Aspirin’s action in reducing inflammatory bio-
markers has been inconsistently demonstrated.
In a randomized crossover trial of 40 patients
with chronic stable angina, MCSF, IL-6, and
CRP were all reduced after 6 weeks of 300 mg
aspirin compared to placebo (Ikonomidis et al.,
1999). In 121 patients with metabolic syndrome
randomized to aspirin for 2 weeks, aspirin 100
mg/day and 300 mg/day significantly decreased
blood levels of high sensitivity (hs)-CRP and
thromboxane B2 compared to baseline (Gao et al.,
2009). Both hs-CRP and TNF-α were significantly
decreased by 100 mg aspirin daily at 7 and
30 days in a randomized trial of 115 patients
with non-ST-segment elevation acute coronary
syndrome (Chen et al., 2006). In the 16,297 adults
≥45 years old from the REGARDS cohort, the
combined use of aspirin and statins was associated
with synergistically lowered CRP concentrations,
especially among participants taking aspirin for
>5 years (Fisher et al., 2008). Another five trials
in clinical cohorts did not demonstrate a reduction
in inflammatory markers, although most comprised
small sample sizes and were therefore potentially
subject to a type 2 error. On the basis of this data
it appears that aspirin in the dose employed in
ASPREE may have a modest but variable effect on
suppressing biomarkers of inflammation.
Preclinical data in depression
There is a preclinical evidence base, with salient
findings including that combined treatment of
fluoxetine and aspirin reversed an animal model
of depression more rapidly than fluoxetine alone
(Brunello et al., 2006). In addition, aspirin
treatment significantly improved depressive-like
behaviors in a rat model of resistant depression
(Wang et al., 2011).
Epidemiological and clinical data
There is limited clinical evidence to support a
role of aspirin in modulating mood disorders.
In one study, patients receiving aspirin at the
time of coronary angiography were less likely to
have depressive symptoms. In a large European
record linkage study, patients on lithium for
bipolar disorder who were concurrently receiving
low-dose aspirin were substantially less likely to
have new medication events, the index of mood
instability in the study. Almeida showed that aspirin
reduced the risk for depression, although this effect
was only evident in those with baseline elevated
risk biomarkers, particularly plasma homocysteine
levels. However, a study of 5,556 older men
showed no association between current aspirin use
and depression, although men who discontinued
aspirin had a greater odds ratio for depression
than those not using aspirin (Almeida et al.,
2010).
Epidemiological data suggests that aspirin
exposure is associated with a reduced risk of de-novo
depression. In a nested case control study within
the Geelong Osteoporosis Study, an age-stratified
community sample of 1,494 women randomly
selected from electoral rolls that was followed up
over a period of 10 years. One hundred and
four women had been exposed to aspirin; median
duration of exposure was 7.0 years (IQR 2.1–
10.0). Exposure to aspirin was associated with a
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trend towards an age-adjusted reduction in risk
for de-novo MDD, with an OR of 0.18 (95%CI
0.02–1.39, p = 0.1). Exposure to aspirin was
documented for 1 of 22 depression cases and 103 of
323 controls (5% vs. 32%, p = 0.007) (Pasco et al.,
2010a). The relationship between aspirin exposure
and depression risk has also been examined in
men in the same study. Among 139 exposed and
803 non-exposed men followed for 5 years, aspirin
was associated with an OR of 0.18 (0.07–0.44
p = 0.00; unpublished data) for less depression.
Although observational data alone does not provide
strong evidence of efficacy it provides a rationale
for a definitive assessment in a randomized placebo-
controlled trial.
There is also clinical trial evidence suggesting
possible beneficial effects of aspirin when given
concurrently with antidepressant medication in
depression. In an observational study of 70 patients
with depression, administration of aspirin together
with fluoxetine conferred a greater reduction in
biochemical markers of oxidative stress compared
with fluoxetine alone. In another study, there
appeared to be an accelerated antidepressant
response to antidepressants with adjuvant aspirin
(Mendlewicz et al., 2006). A number of anti-
inflammatory agents as diverse as celecoxib,
pioglitazone, and infliximab have also shown
promising efficacy in depression (Maes et al.,
2012b). In aggregate, this evidence is not of
sufficient strength to warrant change in clinical
practice, but is supportive of the role of this study.
ASPREE study design
Overview of the ASPREE principal trial
ASPREE is a multi-center, randomized, double-
blinded, placebo-controlled trial of daily 100
mg enteric-coated aspirin in 19,114 healthy
community dwelling older adults in Australia and
the USA. Age eligibility is 65 years and over
(African Americans and Hispanics in the USA)
and all others aged 70 years and over. The aim
of ASPREE is to determine whether 100 mg
aspirin daily extends disability-free and dementia-
free survival in the elderly, and is a primary
prevention study. The trial is conducted according
to the requirements of the Australian National
Statement on Ethical Conduct in Human Research
(Australian Government, NHMRC, 2007) and the
Australian Code for the Responsible Conduct of
Research and has been approved by institutional
review boards at all sites, adhering to the ethical
principles mandated by the 2008 Declaration
of Helsinki and encompasses the protocol items
recommended by the International Conference on
Harmonisation Good Clinical Practice E6 guid-
ance. The protocol was developed in accordance
with Standard Protocol Items Recommendations
for Intervention Trials (SPIRIT) 2013 guidelines,
and will be reported using CONSORT guidelines
and registered on ClinicalTrials.gov Identifier:
NCT01038583.
The ASPREE study methods have been de-
scribed in detail elsewhere (ASPREE Investigator
Group, 2013). In brief, the majority of ASPREE
participants have been recruited through part-
nerships with general practitioner co-investigators.
A minority has been recruited directly from the
community.
Inclusion criteria include men and women who
are able to give informed consent and able to
attend a study visit. Exclusion criteria include a
past history of cardiovascular event or established
cardiovascular disease (including stroke, transient
ischemic attack, myocardial infarction, unstable
angina, coronary artery reperfusion procedures
and bypass grafting, abdominal aortic aneurysm,
cardiac failure), atrial fibrillation, dementia or
score of <78 on Modified Mini-Mental State
(3MS) examination, disability as defined by severe
difficulty or inability to perform anyone of the
Katz activities of daily living (ADLs) at the time
of randomization, a condition with a high current
or recurrent risk of bleeding, anemia, a condition
likely to cause death within 5 years, current use
of other antiplatelet or antithrombotic medication,
current use of aspirin for secondary prevention, and
uncontrolled hypertension.
Randomization of study drug follows a block
randomization procedure and is stratified by site
and age (65–79 and >80 years). Participants were
randomized to receive either 100 mg of enteric
coated aspirin or an enteric coated placebo, which
were identical in appearance, in a ratio of 1:1,
with study participants, investigators and general
practitioner co-investigators blinded to allocation.
The ASPREE study began in 2010, completed
recruitment in December 2014 (16,703 in Australia
and 2,411 in the USA) and will conclude in
2017/2018.
The primary ASPREE endpoint is a composite
of death or dementia (adjudicated according to
the DSM-IV criteria) or persistent loss of the
same Katz ADL. Pre-specified secondary endpoints
include death, cardiovascular and cerebrovascular
disease, cancer, cognitive impairment, depression,
physical disability, and clinically significant bleed-
ing. All clinical and safety endpoints, especially
bleeding, are adjudicated by independent end-
point adjudication committees who are provided
with de-identified clinical information about the
event.
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Study design of ASPREE-D (depression)
ASPREE-D is a sub-study of the ASPREE
principal clinical trial, and has been approved by
the ASPREE International Steering Committee.
The primary outcome variable will be a diagnosis
of an episode of MDD defined as CES-D-10 item
scale score of 8 or above. As some participants may
have a CES-D score of 8+ at baseline or a past
history of depression, the study aims to look at
both incident and recurrent depression. The CES-
D self-completed questionnaire rates the severity of
depressive symptoms in general populations. Use
of self-rated scales obviates inter-rater variability
issues in multi-site studies. It has been extensively
validated across different cultural groups and
the elderly (Dozeman et al., 2011). It identifies
depression in the elderly with or without cognitive
impairment and has a single factor structure. Using
the Structured Clinical Interview for DSM-IV as
the reference, the sensitivity and specificity of the
CES-D was 82% and 83% respectively (Ghubash
et al., 2000) in one study, 74% and 87% respect-
ively for current major depression or dysthymia in a
second study (Tuunainen et al., 2001).
The CES-D was administered initially at
baseline and at each odd year of follow-up
(1, 3, 5, or 7 years). Upon receipt of further
funding we more recently have added CES-D
assessments to the intervening even years (2, 4, and
6 years). Hence in ASPREE-D, participants will
be measured for depression annually until the end
of their participation in the study. The Quality
of life Short Form–12 (SF-12) is a secondary
outcome measure of ASPREE-D. It is a 12-item
self-rated generic tool to assess functional health
and well-being, with physical component summary
(PCS) and mental component summary (MCS)
scores.
Baseline bloods are already collected on the ma-
jority of Australian ASPREE participants through
the ASPREE Healthy Ageing Biobank, approxim-
ately 8,500 prior to starting trial medication, with
approximately 6,800 of these contributing a follow-
up year three sample and approximately 5,000
of these still on randomized study medication.
We plan to measure biomarkers at baseline and
at 3 years follow up in this sub-sample of
5,000 participants. Inflammatory biomarkers to
be measured in the sub-sample of cases and
controls include hs-CRP, IL-6, and TNF-α, based
on recent meta-analyses highlighting these as the
key biomarkers of depression risk (Hiles et al.,
2012).
For the primary hypothesis, the target ASPREE
sample size was 19,000. To assess power for testing
the primary hypothesis that aspirin will reduce the
risk of depression over the 5 years of the study,
we assume based on the extant literature that the
risk of depression at any time point in the placebo
group is 10%. We assume a correlation of 0.6
between baseline and follow up measurements of
depression with a compound symmetry correlation
pattern. With a 5% significance level, and assuming
a 5% drop out rate per year over 5 years, we have
90% power to detect an odds ratio of 0.9 when
comparing depression risk in the aspirin group to
the placebo group.
For secondary hypothesis 1, using simulation
techniques, the smallest detectable effect size for
continuous biomarker levels, based on 90% power
in multivariate logistic regression models for each
biomarker fitted to data from 2,500 in the aspirin
group and 2,500 controls, is an odds-ratio of 1.05
for each μg/ml unit increase of CRP level, 1.1
for each ng/ml unit increase of TNF-α level and
1.003 for each pg/ml unit increase of IL-6 level.
For secondary hypothesis 2, the study will have
90% power to detect 0.5 μg/ml (SD = 3) difference
in CRP, 0.3 ng/ml (SD = 2) difference in TNF-
α and 6 pg/ml (SD = 40) difference in IL-6. For
secondary hypothesis 3, we use the assumed 0.9
reduction in the odds of depression due to aspirin
(from the primary hypothesis) and additionally
assume a 1.3 fold increase in odds of depression
associated with a “high” biomarker change based
on a dichotomization of biomarker change scores
into “high”/“low”. Based on these assumptions
the study has 90% power to detect an odds-ratio
of 0.5 for the interaction effect of aspirin/placebo
group allocation and low/high biomarker change.
Power will be greater for analysis of this interaction
with biomarker change on a continuum. All these
calculations for secondary hypotheses are based on
two-sided 0.01 type I error to allow for multiple
comparisons.
All randomized ASPREE participants will have
their CES-D outcome for each time point included
in a logistic regression model that includes
the covariate treatment group (with odds ratios
estimated using generalized estimating equations
with an exchangeable working correlation matrix
to take account of the repeated measures for each
participant). The primary outcome will be analyzed
according to intention-to-treat principles. A pre-
specified sub-group analysis will be performed by
lifetime history of depression at baseline inclusive
of a baseline CES-D of 8+, in order to look
at aspirin’s effect on recurrent as well as de
novo depression. A secondary analysis will be
conducted in which participants’ CES-D outcomes
will be removed from analysis from the time that
they experience a life-limiting illness, specifically
stroke, CVD, cancer (excluding non-melanoma
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skin cancer), or dementia. If necessary, a secondary
set of analyses will be performed to adjust for
any baseline characteristics that are found to
be imbalanced between groups to the extent of
a 0.25 standard deviation difference in means
(quantitative measures) or an odds ratio of 1.5
(binary measures).
All analyses of secondary hypotheses related to
inflammatory biomarker levels will be based on
the nested case control study. Logistic regression
will be used to compare baseline biomarker levels
between cases and controls to address secondary
hypothesis 1. Secondary hypothesis 2 will be
analyzed by comparing the change in biomarkers
from baseline to 3 years post randomization
between the aspirin and placebo groups using
analysis of covariance to adjust for baseline
biomarker levels. For secondary hypothesis 3,
logistic regression for the outcome depression
(case/control status) will include treatment group,
biomarker level at baseline, and baseline to year
three change in biomarker as predictors. The model
will include an interaction effect between treatment
group and change in biomarker level to test the
hypothesis. A second analysis will be undertaken
with biomarker change dichotomized to enhance
clinical interpretation. All of the analyses for each
secondary hypothesis will adjust for the baseline
characteristics, age, sex, comorbidity, concomitant
medication, and lifetime history of depression.
For hypothesis 4, that low-dose aspirin improves
quality of life, assessed using the Quality of life
Short Form–12 (SF-12), in healthy individuals over
65 years of age at least in part by reducing
depression, we will undertake mediation analyses
of aspirin’s effect on QoL including the effects of
CES-D. Finally, for hypothesis 5, that treatment
with low-dose aspirin in those with baseline
depression (high CES-D at baseline) will reduce
the severity of depression compared with placebo-
treatment, we will test whether mean CES-D-10
scores in subsequent years will be lower in those
treated with aspirin compared with placebo in those
with pre-existing depression using linear mixed
models repeated measures.
Intention-to-treat analyses and dealing with
missing outcome data
In additional secondary analyses, missing baseline
and follow-up outcome data will be estimated
through multiple imputation based on missing not
at random assumption. Analyses based on imputed
data will be reported as part of the sensitivity
analyses using four-point framework that has been
proposed to deal with this issue.
Summary
Depression produces the second-highest burden
of illness worldwide. This reflects both the
direct treatment costs of this disorder, and its
broader impacts on other medical treatments,
hospital outpatient medical care, and increased
requirements for institutional care. Despite the
available standard depression treatments, a large
proportion of the patients with depression do not
achieve remission of depressive symptoms (typically
∼ 30%) and most patients with depression
experience a chronic illness course with multiple
relapses over time. In this context, it needs to be
stressed that in most branches of medicine, the
greatest successes have been in prevention, and
psychiatry to date has largely lacked a preventive
agenda or a preventive evidence base.
ASPREE-D provides an opportunity to compre-
hensively establish whether an anti-inflammatory
and antithrombotic agent – aspirin – can prevent
the development of depression in the elderly. Large-
scale prevention studies in psychiatry are rare.
This study will be the first large-scale study of
a preventative pharmacotherapy for depression.
The size of the proposed study will likely give a
definitive answer to the research hypotheses being
proposed. Given the overall prevalence of MDD in
this population, even a very small reduction in the
incidence of depression will have a long-standing
and substantive impact, at a population level and
for the cost of medical care. This study may have
an immediate and direct translational impact in
establishing the role for aspirin in the prevention
of depression in the elderly and exploring its
relationship to quality of life, aided by the very
low cost of the intervention. This study also will
serve as a proof of concept confirmation of the
inflammatory theory of depression, and establish
the role of anti-inflammatory agents in both the
primary and secondary prevention of depression,
as well as in symptom reduction. This is likely
to support the exploration of other treatment
approaches targeting these pathways in both the
prevention and treatment of depression, both in the
elderly and in younger age groups.
Lastly, the numerator of benefit has to be
balanced against the denominator of risk. For
any preventive intervention rolled out across a
community, the greater the number of disorders
that may benefit, the greater the viability of the
intervention. The use of aspirin in this age group
as a preventative agent will thus be influenced
by its broader efficacy and safety impact on a
range of disorders that are major outcomes of the
principal ASPREE study, including cardiovascular,
cerebrovascular disease, and cancer. Similarly, a
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trial of this size is unique in psychiatry and
only possible embedded in an existing RCT.
Given that shared risk pathways such as diet,
smoking and physical activity contribute to the non-
communicable disorders, and appear to contribute
to inflammation, this trial is an exemplar of an
integrated approach to prevention (O’Neil et al.
2015).
Conflicts of interest
MB has received Grant/Research Support from
Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline,
Meat and Livestock Board, Organon, Novartis,
Mayne Pharma, Servier, and Woolworths, has
been a speaker for Astra Zeneca, Bristol Myers
Squibb, Eli Lilly, Glaxo SmithKline, Janssen
Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo,
Servier, Solvay and Wyeth, and served as a
consultant to Astra Zeneca, Bioadvantex, Bristol
Myers Squibb, Eli Lilly, Glaxo SmithKline,
Janssen Cilag, Lundbeck Merck, and Servier. RCS
receives research support from Eli Lilly & Co.,
Inc., Genentech, Inc., Merck & Co., Inc., H.
Lundbeck A/S,Navidea Biopharmaceuticals, and
Takeda Development Center Americas, Inc., and
Toyama Chemical Co., Ltd., as a Site PI or a Site
Subinvestigator. MRN has participated in trials that
have received funding from SmithKline Beecham,
AstraZeneca, Bayer, Sanofi-Aventis, Merck Sharpe
and Dohme, Pfizer, Servier Laboratories and
Bristol-Myers Squibb, has served on advisory
boards for Sanofi-aventis, Novartis, Schering-
Plough Solvay Pharmaceuticals and AMGEN,
has prepared educational material for Servier
Laboratories, AstraZeneca Bristol-Myers Squibb
and MediMark and has received conference and
travel support from Bayer HealthCare AG, Merck
Sharpe and Dohme, Novartis and Sanofi-aventis.
Description of authors’ roles
All authors contributed to study design and
manuscript preparation.
Acknowledgements
The ASPREE-D study is funded by a project
grant from the NHMRC (1081901). The ASPREE
principal study which recruited participants and
is responsible for all follow-up measurements
including clinical endpoints, SF-12 and other data
capture is funded primarily by a grant from the
US National Institute on Aging (1R01AG029824-
01A2) with additional support from Australia’s
NHMRC (ID334047), the Victorian Cancer
Agency and Monash University. The ASPREE
Healthy Ageing Biobank, which collected the
blood samples for measures of inflammatory
biomarkers for this study, was funded by a
Flagship Cluster Collaboration award from the
CSIRO and from the National Cancer Insti-
tute through a supplement (5U01AG029824-
02 (ASPREE 07210)) to the NIH ASPREE
grant. ASPREE is registered on the International
Standard Randomized Controlled Trial Number
Register (ISRCTN83772183). Bayer Pharma AG
provides blinded aspirin and placebo. ASPREE has
multiple IRB approvals in the US and Australia.
MB is supported by a NHMRC Senior Principal
Research Fellowship 1059660. AMM receives
research support from the National Institutes of
Health. CMR receives research support from the
NHMRC (Program grant 1092642) and the Heart
Foundation and is supported by a NHMRC Senior
Research Fellowship (1045862).
References
Alexopoulos, G. S. (2005). Depression in the elderly. Lancet,
365, 1961–1970.
Almeida, O. P., Alfonso, H., Jamrozik, K., Hankey, G. J.
and Flicker, L. (2010). Aspirin use, depression, and
cognitive impairment in later life: the health in men study.
Journal of the American Geriatrics Society, 58,
990–992.
Ancill, R. J. and Holliday, S. G. (1990). Treatment of
depression in the elderly: a Canadian view. Prog
Neuropsychopharmacol Biol Psychiatry, 14, 655–661.
ASPREE Investigator Group (2013). Study design of
ASPirin in reducing events in the elderly (ASPREE): a
randomized, controlled trial. Contemporary Clinical Trials,
36, 555–564.
Australian Government, NHMRC. (2007). National
Statement on Ethical Conduct in Human Research (2007)
- Updated May 2015. Available at:
https://www.nhmrc.gov.au/guidelines-publications/e72.
Berk, M. et al. (2013). Aspirin: a review of its
neurobiological properties and therapeutic potential for
mental illness. BMC Medicine, 11, 74.
Brunello, N. et al. (2006). Acetylsalicylic acid accelerates the
antidepressant effect of fluoxetine in the chronic escape
deficit model of depression. International Clinical
Psychopharmacology, 21, 219–225.
Chen, Y. G. et al. (2006). Effect of aspirin plus clopidogrel
on inflammatory markers in patients with non-ST-segment
elevation acute coronary syndrome. Chinese Medical Journal
(Engl), 119, 32–36.
Cuijpers, P., van Straten, A., Smit, F., Mihalopoulos, C.
and Beekman, A. (2008). Preventing the onset of
depressive disorders: a meta-analytic review of
psychological interventions. American Journal of Psychiatry,
165, 1272–1280.
8 M. Berk et al.
Dean, B., Tawadros, N., Scarr, E. and Gibbons, A. S.
(2010). Regionally-specific changes in levels of tumour
necrosis factor in the dorsolateral prefrontal cortex
obtained postmortem from subjects with major depressive
disorder. Journal of Affective Disorders, 120, 245–248.
Dozeman, E., van Schaik, D. J., van Marwijk, H. W.,
Stek, M. L., van der Horst, H. E. and Beekman, A. T.
(2011). The center for epidemiological studies depression
scale (CES-D) is an adequate screening instrument for
depressive and anxiety disorders in a very old population
living in residential homes. International Journal of Geriatric
Psychiatry, 26, 239–246.
Fisher, M., Cushman, M., Knappertz, V. and Howard,
G. (2008). An assessment of the joint associations of
aspirin and statin use with C-reactive protein
concentration. American Heart Journal, 156, 106–111.
Gao, X. R. et al. (2009). Efficacy of different doses of aspirin
in decreasing blood levels of inflammatory markers in
patients with cardiovascular metabolic syndrome. Journal of
Pharmacy and Pharmacology, 61, 1505–1510.
Ghubash, R., Daradkeh, T. K., Al Naseri, K. S., Al
Bloushi, N. B. and Al Daheri, A. M. (2000). The
performance of the center for epidemiologic study
depression scale (CES-D) in an Arab female community.
International Journal of Social Psychiatry, 46, 241–249.
Hiles, S. A., Baker, A. L., de Malmanche, T. and Attia,
J. (2012). A meta-analysis of differences in IL-6 and IL-10
between people with and without depression: exploring the
causes of heterogeneity. Brain Behavior and Immunity, 26,
1180–1188.
Ikonomidis, I., Andreotti, F., Economou, E., Stefanadis,
C., Toutouzas, P. and Nihoyannopoulos, P. (1999).
Increased proinflammatory cytokines in patients with
chronic stable angina and their reduction by aspirin.
Circulation, 100, 793–798.
Jenny, N. S. et al. (2012). Long-term assessment of
inflammation and healthy aging in late life: the
cardiovascular health study all stars. The Journals of
Gerontology, Series A Biological Sciences and Medical Sciences,
67, 970–976.
Krishnadas, R. and Cavanagh, J. (2012). Depression: an
inflammatory illness? Journal of Neurology, Neurosurgery &
Psychiatry, 83, 495–502.
Liu, Y., Ho, R. C. and Mak, A. (2012). Interleukin (IL)-6,
tumour necrosis factor alpha (TNF-alpha) and soluble
interleukin-2 receptors (sIL-2R) are elevated in patients
with major depressive disorder: a meta-analysis and
meta-regression. Journal of Affective Disorders, 139,
230–239.
Maes, M. et al. (2012a). Depression and sickness behavior
are Janus-faced responses to shared inflammatory
pathways. BMC Medicine, 10, 66.
Maes, M., Fisar, Z., Medina, M., Scapagnini, G.,
Nowak, G. and Berk, M. (2012b). New drug targets in
depression: inflammatory, cell-mediated immune, oxidative
and nitrosative stress, mitochondrial, antioxidant, and
neuroprogressive pathways. And new drug candidates–Nrf2
activators and GSK-3 inhibitors. Inflammopharmacology,
20, 127–150.
Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D.,
Alboni, S. and Brunello, N. (2006). Shortened onset of
action of antidepressants in major depression using
acetylsalicylic acid augmentation: a pilot open-label study.
International Clinical Psychopharmacology, 21,
227–231.
Moylan, S., Maes, M., Wray, N. R. and Berk, M. (2013).
The neuroprogressive nature of major depressive disorder:
pathways to disease evolution and resistance, and
therapeutic implications. Molecular Psychiatry, 18,
595–606.
O’Neil, A. et al. (2015) A shared framework for the common
mental disorders and non-communicable disease: key
considerations for disease prevention and control. BMC
Psychiatry. 5, 15.
Palsson, S. P., Ostling, S. and Skoog, I. (2001). The
incidence of first-onset depression in a population followed
from the age of 70 to 85. Psychological Medicine, 31,
1159–1168.
Pasco, J. A. et al. (2010a). Clinical implications of the
cytokine hypothesis of depression: the association between
use of statins and aspirin and the risk of major depression.
Psychotherapy and Psychosomatics, 79, 323–325.
Pasco, J. A. et al. (2010b). Association of high-sensitivity
C-reactive protein with de novo major depression. British
Journal of Psychiatry, 197, 372–377.
Tuunainen, A., Langer, R. D., Klauber, M. R. and
Kripke, D. F. (2001). Short version of the CES-D
(Burnam screen) for depression in reference to the
structured psychiatric interview. Psychiatry Research, 103,
261–270.
Wang, Y., Yang, F., Liu, Y. F., Gao, F. and Jiang, W.
(2011). Acetylsalicylic acid as an augmentation agent in
fluoxetine treatment resistant depressive rats. Neuroscience
Letters, 499, 74–79.
